Monitor the upcoming Phase 1 data presentation for JADE101 at the ERA Congress for clinical proof-of-concept; data could be a major catalyst if safety/efficacy are favorable. The EPS miss is secondary for a pre-revenue biotech.
Price Chart
Executive Summary
Jade Biosciences reported Q1 2026 EPS of -$0.57, missing consensus of -$0.52 by 9.6%. Net loss widened to $40.4M from $38.2M YoY as R&D spend increased 80% to $36.1M. Cash burn continues ($311M vs $336M in Dec 2025), but the pipeline focus remains on upcoming Phase 1 data for JADE101 at the ERA Congress.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP EPS -$0.57 vs consensus -$0.52 (miss of -9.6%)
- Cash, cash equivalents and investments: $311.3M as of March 31, 2026 (vs $336.2M at year-end 2025)
- Net loss: $40.4M in Q1 2026 vs $38.2M in Q1 2025
- R&D expenses: $36.1M, up 80% YoY
- Phase 1 interim biomarker data for JADE101 to be presented in an oral session at the 63rd ERA Congress
- Phase 2 trial for JADE101 in IgAN expected to start Q2 2026
- JADE201 Phase 1 in RA expected to start Q2 2026
- Appointed Edward R. Conner, M.D. as CMO; promoted Dr. Andrew King to President, R&D
Financial Impact
Net loss increased 6% YoY to $40.4M; cash burn of ~$25M in Q1 2026
Risk Factors
- Clinical failure or delay of JADE101 Phase 2 or JADE201 Phase 1
- Cash runway may shorten if development costs escalate faster than expected
- Dilution from convertible notes (fair value changes impacted net loss in prior quarters)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-211973 |
| Document: d108669d8k.htm | 0001193125-26-211973 |
| Document: 0001193125-26-211973-index-headers.html | 0001193125-26-211973 |
| Document: 0001193125-26-211973-index.html | 0001193125-26-211973 |
| Document: 0001193125-26-211973.txt | 0001193125-26-211973 |
| 8-K Data (Synthetic) | 0001193125-26-211973 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 8-K | $14.05 $13.77 | ▼ −1.99% | ▼ −3.91% | $14.50 (+3.20%) |
Aug 10, 2026 11w ago | 8-K | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Aug 10, 2026 11w ago | Press Release | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Jun 5, 2026 20w ago | Press Release | $14.98 $16.10 | ▼ −7.48% | ▼ −5.37% | $14.50 (+3.20%) |
Jun 4, 2026 20w ago | 8-K | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 4, 2026 20w ago | 424B5 | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | 424B5 | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 1, 2026 21w ago | 8-K | $18.59 $16.94 | ▼ −8.88% | ▼ −6.13% | $14.50 (−22.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers